How Does Naltrexone Work for Weight Loss?

Naltrexone works for weight loss not on its own but in combination with bupropion, an antidepressant. The two drugs target appetite-regulating neurons in the brain, and the combination, sold under the brand name Contrave, produces a placebo-subtracted weight loss of roughly 5 percent of body weight over a year. That makes it a moderate performer in the current landscape of obesity medications, but the way it achieves its effect through reward-pathway suppression sets it apart from drugs that work primarily on hunger hormones.

What Happens in the Brain

The key to understanding naltrexone’s role in weight loss is a group of nerve cells in the hypothalamus called POMC neurons. These neurons release chemicals that suppress appetite when they’re activated. Bupropion, originally developed as an antidepressant and smoking-cessation aid, stimulates POMC neurons and triggers that appetite-suppressing signal. But here’s the catch: POMC neurons have a built-in feedback loop. When they fire, they also release beta-endorphin, an opioid the body makes naturally, which circles back and dampens their own activity. In practical terms, bupropion turns on the appetite brake, but the brake partially releases itself.

Naltrexone is an opioid receptor blocker. It was originally approved for treating alcohol and opioid dependence. When paired with bupropion, naltrexone blocks that self-dampening opioid signal on POMC neurons, letting bupropion’s appetite-suppressing effect last longer and hit harder. The combination stimulates POMC neurons through bupropion and then removes the autoinhibitory brake through naltrexone.¹ Neither drug alone produces meaningful weight loss in most people; they need each other to generate the combined effect.

The Role of Food Cravings and Reward

Beyond the hypothalamic appetite circuit, naltrexone appears to influence how rewarding food feels. People with obesity sometimes describe food cravings that go beyond ordinary hunger, a pull toward eating that has more in common with compulsive behavior than with a simple need for calories. Because naltrexone blocks opioid receptors, it can blunt the pleasure signal that certain foods produce, especially in people who are particularly driven by food reward.

A pilot study in women with obesity found that on placebo days, people who scored high on reward-based eating had stronger food cravings, as you’d expect. But on days when they took naltrexone at a 50 mg dose, that link between reward-driven eating and craving intensity was broken. The drug seemed to selectively dampen cravings in the people who were most reward-sensitive.² That study was small, but it points to a mechanism that matters: naltrexone may be especially useful for people whose eating is driven by reward and craving rather than by physical hunger alone.

How Much Weight People Actually Lose

The FDA approval of naltrexone/bupropion rested on a series of large phase 3 clinical trials called the COR (Contrave Obesity Research) program. The numbers across those trials are consistent enough to give a reliable picture.

In COR-I, which enrolled over 1,700 participants, people taking the higher-dose combination (naltrexone 32 mg plus bupropion 360 mg daily) lost about 6.1 percent of their body weight over 56 weeks, compared with 1.3 percent for placebo. Nearly half of the drug group lost at least 5 percent of their starting weight, compared with about one in six on placebo.³ In COR-II, the drug group lost about 6.5 percent at 28 weeks, and that loss held steady through week 56 at 6.4 percent, while the placebo group drifted back to just 1.2 percent lost.⁴

A meta-analysis pooling data across the trial program found naltrexone/bupropion produced about 5 kg more weight loss than placebo, with roughly four times the odds of achieving at least 5 percent weight loss.⁵ Pooling all four phase 3 trials, the placebo-subtracted mean weight loss comes to about 4.7 percent, and in patients with type 2 diabetes, the combination also lowered hemoglobin A1c by about half a percentage point more than placebo.⁶

For someone weighing 220 pounds, a 5 percent loss is about 11 pounds. That is enough to produce measurable health improvements in blood pressure, blood sugar, and cholesterol, but it is far from the dramatic transformations associated with newer injectable medications.

How It Stacks Up Against Newer Drugs

The weight-loss drug landscape has shifted dramatically with the arrival of GLP-1 receptor agonists like semaglutide. A large network meta-analysis comparing all major obesity drugs found that semaglutide produced about 9 kg more weight loss than placebo at 12 months, and phentermine/topiramate produced about 8 kg more. Naltrexone/bupropion, while effective, sits in a lower tier in terms of raw pounds lost.⁷

That does not make naltrexone/bupropion irrelevant. It is taken as a pill, not injected, which matters to the many people who dislike or cannot tolerate injections. It is generally less expensive than semaglutide. And it was among the least costly medications in a cost-effectiveness analysis comparing five obesity drugs from a US payer perspective, with quality-of-life outcomes that differed by no more than half a quality-adjusted life year across all options.⁸ For people who cannot access or afford a GLP-1 drug, or who have contraindications to it, naltrexone/bupropion remains a reasonable oral alternative.

Side Effects and What to Expect Early On

Nausea is the most common complaint, and it is not subtle. In clinical trials, about 31 percent of people taking naltrexone/bupropion reported nausea, compared with roughly 7 percent on placebo. Those who experienced nausea were also more likely to report vomiting, headache, dizziness, and diarrhea, though severe vomiting affected less than 1 percent of participants in either group.⁹

An important finding from that same study: weight loss was similar in people who experienced nausea and those who did not. In other words, the drug works through the brain mechanisms described above, not by making you too nauseated to eat. If you do experience nausea, it tends to be worst in the first few weeks and generally fades. The standard prescribing approach involves a four-week dose escalation, starting at one tablet daily and building to the full dose of two tablets twice daily, specifically to reduce early side effects.

Beyond nausea, the drug carries more serious but rare warnings. Bupropion lowers the seizure threshold, so naltrexone/bupropion is contraindicated in people with seizure disorders. In rare cases, suicidal thoughts have been reported, likely related to bupropion’s antidepressant mechanism, leading to a boxed warning about suicidality, particularly in younger adults.¹⁰ Anyone starting this medication should be monitored for mood changes, especially in the early weeks.

The Cardiovascular Question

Because bupropion can raise blood pressure and heart rate slightly, regulators wanted to know whether naltrexone/bupropion increased the risk of heart attacks and strokes. The story here got complicated. An FDA-mandated cardiovascular outcomes trial called the Light Study was launched, but it was terminated early after interim data were publicly released in a way that could have unblinded the study. The data collected before termination showed that blood pressure increases with the drug averaged less than half a millimeter of mercury, and heart rate increased by less than one beat per minute compared with placebo.¹¹

A systematic review looking across all available human evidence found no increased risk of major cardiovascular events among users of naltrexone/bupropion, naltrexone alone, or bupropion alone. The difference in event rates between drug-treated and placebo-treated patients never exceeded 2.5 percent for any component of major cardiovascular events.¹² The drug also shows improvements in cardiometabolic markers like cholesterol and blood sugar, likely because of the weight loss itself.¹³ Still, the premature end of the Light Study means we have less long-term safety data than we’d like, and the FDA does still note unresolved cardiovascular concerns on the label.

Binge Eating and Whether the Drug Helps

Given that naltrexone targets opioid-driven reward and bupropion affects dopamine, you might expect this combination to be a natural fit for binge-eating disorder. The evidence here is genuinely mixed.

One randomized trial specifically testing naltrexone/bupropion for binge-eating disorder found that the drug did produce weight loss in participants with BED, but it did not reduce binge-eating frequency significantly more than placebo.¹⁴ In other words, people lost weight but kept bingeing at similar rates.

A separate trial that combined the medication with behavioral weight-loss therapy told a more nuanced story. In that study, binge-eating remission rates were about 18 percent with placebo, 31 percent with naltrexone/bupropion alone, 37 percent with behavioral therapy plus placebo, and 57 percent with both the drug and behavioral therapy together. Both the medication and behavioral therapy independently improved binge-eating remission, but they did not amplify each other, meaning combining them helped more people, but the gains simply stacked rather than multiplied.¹⁵

The takeaway: if you have binge-eating disorder and are considering naltrexone/bupropion, expect it to help with weight but not necessarily with the bingeing itself unless you also work with a structured behavioral program.

Who Responds Best

Not everyone responds equally to naltrexone/bupropion, and researchers have started looking at why. One of the more interesting findings involves genetics. A pilot study examined a variant near the dopamine receptor gene DRD2, known as the Taq1A polymorphism. People carrying the A1+ version of this variant, which is associated with lower dopamine receptor density, lost significantly more weight on naltrexone/bupropion (about 5.9 percent) than people without it (about 4.2 percent). Only the A1+ group hit what researchers considered a clinically meaningful weight-loss target.¹⁶

This is a small, preliminary finding, and nobody is recommending genetic testing before prescribing the drug. But it fits the broader mechanistic picture: if your reward system is wired in a way that makes opioid and dopamine pathways especially influential in your eating behavior, a drug that blocks those pathways may work better for you. Clinicians sometimes use an informal version of this reasoning already, prescribing naltrexone/bupropion preferentially for patients who describe strong food cravings and reward-driven eating rather than, say, patients whose weight gain seems driven more by metabolic or hormonal factors.

Interestingly, a pooled analysis of trial data found that baseline scores on food craving questionnaires did not predict who would lose more weight on the drug versus placebo. So while naltrexone/bupropion did reduce cravings overall, the people who reported the highest cravings at the start did not necessarily lose the most weight.¹⁷ The question of who benefits most remains open, and the honest answer is that predicting individual response is still imprecise.

Keeping the Weight Off After an Intensive Program

One concern with any weight-loss drug is what happens when people stop taking it, or whether the drug can help maintain losses achieved through other means. A study tested naltrexone/bupropion specifically as a maintenance tool in people who had already completed a six-month intensive lifestyle program involving meal replacements and behavior modification. After that initial program, those who took naltrexone/bupropion for six additional months were able to maintain their weight loss, while the placebo group regained weight. A greater proportion of people on the drug maintained their losses or continued losing compared with placebo.¹⁸

This is relevant because weight regain after initial loss is one of the most frustrating and common experiences in obesity treatment. The biology of weight regulation fights to restore lost weight, and having a pharmacological tool that helps sustain losses could change the long-term equation for some people. Whether the drug needs to be taken indefinitely to maintain its benefit is a question clinicians weigh individually, since long-term data beyond a year or two remains limited for this medication.

Who Should Not Take It

There are clear populations for whom naltrexone/bupropion is off the table. Because naltrexone blocks opioid receptors, anyone currently taking opioid medications for pain, or anyone on medication-assisted treatment for opioid dependence with drugs like methadone or buprenorphine, cannot use it. Taking naltrexone in that situation can trigger sudden opioid withdrawal, which is dangerous. The standard recommendation is to be opioid-free for at least seven to ten days before starting naltrexone.

Bupropion’s seizure risk means the combination is contraindicated in people with epilepsy, a history of seizures, or conditions that lower the seizure threshold, including alcohol withdrawal and benzodiazepine withdrawal. It should not be taken alongside monoamine oxidase inhibitors. The black-box warning about suicidal ideation applies particularly to younger adults, and the drug is not approved for anyone under 18. In fact, there are no pediatric studies investigating naltrexone/bupropion’s effects on childhood or adolescent obesity.¹⁹

People with uncontrolled high blood pressure should use the drug cautiously given the small but real increases in blood pressure and heart rate. Pregnant or breastfeeding women should avoid it. And because naltrexone blocks opioid receptors, it can interfere with emergency pain management: if you need surgery or have an accident while on this medication, your medical team needs to know about it so they can plan pain control accordingly. Some prescribers recommend that patients carry an alert card or wear a medical bracelet for this reason.

Naltrexone Alone Versus the Combination

You may encounter claims about naltrexone by itself for weight loss, or about “low-dose naltrexone” (LDN) as a catch-all treatment. The distinction matters. Naltrexone as a solo agent at standard doses does not produce clinically significant weight loss. Its effect on body weight depends on the synergy with bupropion described above. Without bupropion activating POMC neurons, naltrexone’s opioid blockade alone is not sufficient to drive meaningful appetite suppression or weight reduction.

Low-dose naltrexone, typically used at 1.5 to 4.5 mg rather than the 32 mg in Contrave, has attracted interest for various conditions including chronic pain and autoimmune diseases. Some people assume it might help with weight, but the mechanism of LDN is thought to involve brief opioid blockade that paradoxically upregulates endorphin production, a very different pharmacological story from the sustained opioid blockade used in Contrave. The evidence base for LDN and weight loss specifically is thin to nonexistent, and it should not be confused with the FDA-approved naltrexone/bupropion combination.

If a prescriber suggests naltrexone for weight loss, the relevant question is whether they mean the combination product at its approved doses. Naltrexone monotherapy for weight management lacks the evidence to support it, and the drug’s mechanism makes it clear why: one half of a two-drug strategy does not work the same way in isolation.